Survey 2004 | Survey 2008 | |||||||
---|---|---|---|---|---|---|---|---|
Original product companies (n = 16) n (%)a | Generic product companies (n = 7) n (%)a | Total (n = 23) n (%)a | P-value | Original product companies (n = 15) n (%)a | Generic product companies (n = 6) n (%)a | Total (n = 21) n (%)a | P-value | |
Has generic substitution influenced the storage of pharmaceutical products by your company? | ||||||||
No* | 4 (25) | 3 (43) | 7 (30) | 0.626 | 10 (67) | 3 (50) | 13 (62) | 0.631 |
It has caused over-stocking** | 9 (56) | 2 (29) | 11 (48) | 0.371 | 4 (27) | 1 (17) | 5 (24) | 1.000 |
It has caused problems with the expiry date of pharmaceutical products*** | 7 (44) | 4 (57) | 11 (48) | 0.667 | 3 (20) | 3 (50) | 6 (29) | 0.291 |
It has caused over-stocking of obligatory stocksb **** | 4 (25) | 1 (14) | 5 (22) | 1.000 | 3 (20) | - | 3 (14) | 0.526 |
It has caused problems with the availability of pharmaceutical products***** | 4 (25) | 1 (14) | 5 (22) | 1.000 | 2 (13) | 3 (50) | 5 (24) | 0.115 |
It has complicated the execution of obligatory storageb ****** | 2 (12) | 1 (14) | 3 (13) | 0.684 | 2 (13) | 1 (17) | 3 (14) | 1.000 |
It has increased returns of pharmaceutical products from pharmacies after the new price corridor is determinedc | - | - | - | - | 2 (13) | 1 (17) | 3 (14) | 1.000 |